Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Web Exclusives
Meeting Highlights
ESMO Highlights
Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer
Phoebe Starr
Read More
Biosimilars
Best Practices for Integrating Biosimilars into Your Oncology Practice
Kashyap Patel, MD
Read More
Ovarian Cancer
New MIPS Rule Increases Performance Threshold for Positive Payment Adjustment
Read More
Ovarian Cancer
Combination Therapy May Improve Outcomes for Patients with Ovarian Cancer
Read More
Ovarian Cancer
State and Federal Legislation Addresses PBM Pricing Transparency
Read More
Ovarian Cancer
Proper Management of Toxicities Associated with PARP Inhibitors Is Essential for Optimizing Treatment Outcomes
Read More
Lung Cancer
,
Thyroid Cancer
,
FDA Oncology Update
FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib
Read More
Sarcoma
,
FDA Oncology Update
Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma
Read More
Ovarian Cancer
PARP Inhibitor Use in Ovarian Cancer Expands Beyond Treatment for Recurrent Disease
Read More
Ovarian Cancer
Final Rule Regarding Copay Accumulator Programs May Increase Patients’ Out-of-Pocket Costs for Oral Cancer Drugs
Read More
15
16
17
18
19
20
21
Page 18 of 42
Results 171 - 180 of 417